source
- Taiho and Cullinan's zipalertinib clears Phase 3 trial in EGFR-mutated lung cancerTaiho Oncology and Cullinan Therapeutics announced that their oral EGFR inhibitor zipalertinib successfully completed a registrational Phase 3 study in patients with a specific genetic form of lung…
- PTC Therapeutics and Eli Lilly to acquire parts of bankrupt Sangamo for up to $264 millionThe gene-editing company Sangamo Therapeutics has filed for bankruptcy, placing its assets up for sale. An auction process has identified two bidders: PTC Therapeutics and Eli Lilly, which togethe…